# Hyperpolarized 13C Pyruvate MRI Scan in Predicting Tumor Aggressiveness in Patients With Renal Tumors

> **NCT04258462** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Zhen Wang, MD** · enrollment: 54 (actual)

## Conditions studied

- Benign Kidney Neoplasm
- Kidney Neoplasm
- Renal Cell Cancer

## Interventions

- **DRUG:** Hyperpolarized Carbon C 13 Pyruvate
- **PROCEDURE:** Magnetic Resonance Imaging
- **DRUG:** Hyperpolarized 13C,15N2-urea

## Key facts

- **NCT ID:** NCT04258462
- **Lead sponsor:** Zhen Wang, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-01-15
- **Primary completion:** 2026-10-31
- **Final completion:** 2026-10-31
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2026-02-23

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04258462

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04258462, "Hyperpolarized 13C Pyruvate MRI Scan in Predicting Tumor Aggressiveness in Patients With Renal Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04258462. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*